06:35 AM EDT, 08/13/2024 (MT Newswires) -- Novartis AG ( NVS ) was unable to convince a federal court to stop MSN Pharmaceuticals from launching its own version of the company's heart-failure drug Entresto, a court decision issued on Monday showed.

MSN's version of Entresto was approved by the US Food and Drug Administration on Jul. 24, after which Novartis ( NVS ) asked the court on Aug. 2 for a preliminary injunction to block MSN's launch.

US District Judge Richard Andrews in Delaware ruled that Novartis ( NVS ) was unlikely enough to win its patent-infringement lawsuit challenging the generic to justify halting MSN's launch.

However, Andrews placed a three-day hold on the case and temporarily asked MSN not to sell the drug while Novartis ( NVS ) appeals to the US Court of Appeals for the Federal Circuit.

Novartis ( NVS ) didn't immediately respond to MT Newswires' request for comment on the decision.

Price: 111.31, Change: -0.11, Percent Change: -0.10